

SAVE \$100!  
Register before April 25th  
and Save \$100!

PRESENTS  
THE THIRD ANNUAL  
**BIOTECHNOLOGY  
INDUSTRY  
CONFERENCE**

**MAY 15, 2003**

**THE HARVARD CLUB**

27 WEST 44TH STREET, NEW YORK, NY 10036

SPONSORED BY



**IN THE CURRENT** low-growth and uncertain economic environment, biotechnology represents an attractive high-growth sector for investors. The Wall Street Transcript will examine what the industry is doing to adapt and thrive in this changing marketplace.

**INSIGHT** Join executives as they candidly discuss their perspectives on the industry

**LONG-TERM INVESTMENTS** Where does the industry think investment opportunities lie?

**STRATEGY** Identify successful methods in restructuring, consolidation and the FDA approval process

**BIOFINANCING** Learn innovative financing techniques for today

**RESEARCH** Discover how new technologies and scientific research impact the industry

**STOCK PICKS** Listen to a top analysts' stock recommendations & predictions

PARTNERS:



To register call 212-952-7454, email joanna@twst.com or visit [www.twst.com/conferences](http://www.twst.com/conferences)

# THIRD ANNUAL BIOTECHNOLOGY INDUSTRY CONFERENCE

## A G E N D A

MAY 15, 2003 THE HARVARD CLUB 27 WEST 44TH STREET, NEW YORK, NY 10036

**8:00 AM** Conference Registration & Breakfast

**9:00 AM** **The Big Picture: What's the Buzz on Biotech?**

- Restructuring, Consolidation & Changing FDA Approval Process
- Has the industry gotten past the ImClone fiasco?
- How does Big Pharma fit in the biotech landscape?
- Where does the industry see the short, mid and long-term opportunities?

**Roundtable Participants:**

Alan Smith, PhD, CSO & SVP Research, Genzyme  
Peter Feinstein, General Partner, Bioventures Investors  
Michael Lytton, Partner, Oxford Bioscience Partners  
Andrew Meadow, General Partner, HealthCon Corp.  
Owen Garrick MD, Executive Director & Global Head M&A Negotiations, Novartis Pharma

**Moderator - Jim Shrine, Managing Editor, BioWorld**

**9:45 AM** **Special Presentation: Intellectual Property**

Kevin Noonan, Partner, McDonnell Boehnen Hulbert & Berghoff

**10:15 AM** **Networking Break**

**10:30 AM** **Keynote Address**

Dr. Lester Crawford, Deputy Commissioner, FDA

**11:00 AM** **Mini-Roundtable: Has Biotech turned into long-term investments?**

- Homeland Security Budget Bonanza — Can Biotech thrive on this opportunity?
- Developing new vaccines: Biotech's Hole-in-One?
- Can Bioinformatics and Genomics make a comeback?

**Roundtable Participants:**

Dr. Kenneth Carter, PhD, CEO, Avalon Pharmaceuticals  
Gail Maderis, President, Genzyme Molecular Oncology  
Dr. Jennie Mather, PhD, CEO, Raven Biotechnologies  
Mark Leuchtenberger, CEO, Therion Biologics

**Moderator - Kevin DeGeeter, Editor, Fierce Biotech**

**11:30 AM** **Successful BioFinancing: Where's the money and how is Biotech getting its hands on it?**

- What options exist in this tumultuous equity-financing environment?
- Virtual suspension of the IPO market: Can Biotech companies wait out the storm?
- Can jaded VCs still be of assistance? — greater control, PIPEs, etc.
- Who are the top players in the financing marketplace?

**Roundtable Participants:**

Kurt Kim, CEO, Private Raise  
Dr. Chris Mirabelli, PhD, General Partner, HealthCare Ventures LLC  
Thomas Konatich, CFO/Acting CEO, SIGA Technologies  
Stanley Erck, President & CEO, Iomai Corporation  
Dr. Srinivas Akkaraju, Principal, JP Morgan Partners

**Moderator - Dr. Ginger Johnson, Defined Health**

**12:30 PM** **Luncheon**

**1:45 PM** **Keynote Address**

Dr. Joseph Jasinski, Worldwide Operations Manager, IBM Life Sciences

**2:15 PM** **Special Presentation**

Eileen Smith Ewing, Esq., Partner & Chair, Life Sciences Group, Kirkpatrick & Lockhart

**2:45 PM** **Wall Street Assesses the Industry**

Leading Wall Street professionals examine the industry, key players and direction in an in-depth interview. Valuable opportunity to hear directly from top analysts on the marketplace and preferred stock selections, and ask your questions about specific companies, technologies and forecasts. Audience questions will be taken.

**Roundtable Participants:**

Bill Tanner PhD, Managing Director, Leerink Swann  
Frank DiLorenzo, Analyst, Standard & Poor's  
Maged Shenouda, Analyst, JP Morgan

**Moderator - Terry McEvoy, Coordinating Editor, TWST**

**3:15 PM** **Mini-Roundtable: NBIC—Convergence of Biotech & Other Areas of Scientific Research Nanotechnology, Software and new approaches to science**

- What are the opportunities and pitfalls?
- Who are the key players today and tomorrow?
- Is there potential for significant government funding in this area?

**Roundtable Participants:**

Dr. Vladimir Makarov, Co-Founder & CSO, Rubicon Genomics  
Dr. Rudi Moerck, PhD, President, Altair Nanotechnologies  
Josh Wolfe, Co-Founder & Managing Partner, Lux Capital  
Vijaya Vasista, COO, Nanosphere  
Dr. Juan Sanchez, Research Associate, Punk Ziegel

**Moderator - Salvatore Salamone, Senior IT Editor, Bio IT World**

**4:15 PM** **NETWORKING RECEPTION**

To register call 212-952-7454, email [joanna@twst.com](mailto:joanna@twst.com) or visit [www.twst.com/conferences](http://www.twst.com/conferences)

# Letter from The Wall Street Transcript's Andrew Pickup

“...the partners at MPM Capital insist there's never been a better time to invest in biotech companies.”

— *The Boston Globe, February 24, 2003*

Despite the stock market's volatility, investment trends in biotechnology have remained steady. Biotech has the greatest potential to impact the future of medicine by wiping out a variety of intractable diseases. As more and more biotech advances come to fruition, we can expect a significant increase in the quality of human life and longevity. The potential eradication or control of certain diseases through biotechnology has often translated into tremendous investment opportunities; however, when word broke on the ImClone fiasco, a dark shadow was cast on the entire sector. While the possibilities remains immense for the industry overall, today most public and private biotech firms have undergone severe financial, business and regulatory constraints. As a rule, biotech advances can be expected to be harder to come by and take longer to work. The Wall Street Transcript's 3rd Annual Biotechnology Industry Conference will analyze where the industry is today, what it has been doing to adapt to the changing needs of the market, and what can be expected for the future.

Come join a select group of experts and business executives in the industry. Learn, network and discover what potential business opportunities exist and how best they can be exploited. Learn what specific opportunities should be avoided. Our unique conference format and our combination of financial experts and business executives provide attendees with a unique perspective on the industry. There are many conferences covering the biotechnology industry but none focus on the issues and investment opportunities the way the Transcript does.

Don't miss this event! Call today to register or for complete event information.



Andrew Pickup  
Publisher  
The Wall Street Transcript

PS: Space is limited, so reserve your place now!

## REASONS TO ATTEND

### FOR BIOPHARMACEUTICAL INDUSTRY EXECUTIVES:

- Join executives as they discuss their outlook for the industry
- Determine the right financing methods for your firm
- Gain insight into Wall Street's point of view from leading buy- and sell-side analysts.
- Hear about companies that represent potential alliance acquisition or joint venture

### FOR INVESTORS:

- Learn about the most dynamic biotech sub-sectors
- Understand how consolidation and restructuring are crucial to ongoing success
- An unrivaled opportunity to network with biotech executives and insiders in an informal, intimate setting

### FOR SERVICE PROVIDERS:

- Learn what areas within biotech represent the greatest opportunity for your business
- Network with key decision-makers in the field

## WHO WILL ATTEND

- Senior biotech & pharmaceutical executives
- Consultants to the industry
- Professional investment managers
- Sophisticated individual investors
- Lenders to the industry

## ADMINISTRATION DETAILS

- Register now - availability is limited. Phone, fax, or mail the reply form on the back of the brochure today. Call 212-952-7454, fax 212-668-9842 or email [joanna@twst.com](mailto:joanna@twst.com).
- Special rates for hotel accommodations are being reserved at nearby Helmsley Middletowne Hotel. Call 800-843-2157 for reservations.
- Cancellations – Should you be unable to attend for any reason, please inform us in writing prior to April 28, 2003 and a refund less a \$150 deposit will be issued. No refunds will be given after April 28, 2003. Substitutions for enrolled delegates may be made at any time.
- Please note: Dress is business casual. Please no jeans.

To register call 212-952-7454, email [joanna@twst.com](mailto:joanna@twst.com) or visit [www.twst.com/conferences](http://www.twst.com/conferences)

SAVE \$100!  
Register before April 25th  
and Save \$100!

The Wall Street Transcript

PRESENTS

THE THIRD ANNUAL  
**BIOTECHNOLOGY  
INDUSTRY  
CONFERENCE**

**MAY 15, 2003**

**THE HARVARD CLUB**

27 WEST 44TH STREET, NEW YORK, NY 10036

**Register Before April 25 and  
Receive a \$100 Discount**

\$695 Before April 25, 2003

\$795 On and After April 25, 2003

CALL: (212) 952-7454 OR (866) 589-0538 FAX: (212) 668-9842

WEB: [www.twst.com/conferences](http://www.twst.com/conferences)

OR MAIL TO: THE WALL STREET TRANSCRIPT

67 WALL STREET, 16TH FL

NEW YORK, NY 10005-3701

NAME

COMPANY

TITLE

ADDRESS

CITY

STATE

ZIP

PHONE

FAX

E-MAIL

**METHOD OF PAYMENT:**

PAYMENT ENCLOSED

MAKE CHECK PAYABLE TO: THE WALL STREET TRANSCRIPT

**CREDIT CARD PAYMENT:**

VISA  MASTERCARD  AMEX

CREDIT CARD #

EXP.

SIGNATURE

Registration Form